JP2015535291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535291A5 JP2015535291A5 JP2015540844A JP2015540844A JP2015535291A5 JP 2015535291 A5 JP2015535291 A5 JP 2015535291A5 JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015540844 A JP2015540844 A JP 2015540844A JP 2015535291 A5 JP2015535291 A5 JP 2015535291A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- amount
- therapeutically effective
- effective amount
- pomalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003734 Kidney Anatomy 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001771 impaired Effects 0.000 claims 1
- 229960000688 pomalidomide Drugs 0.000 claims 1
Claims (1)
- 腎臓に障害のある対象において、癌の一又は二以上の症状を治療、予防、又は管理する方法であり、当該対象に治療有効量のポマリドミドを投与することを含み、ここで、当該治療有効量は、腎臓に障害のない対象に投与される量よりも少ない量である、前記方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722722P | 2012-11-05 | 2012-11-05 | |
| US61/722,722 | 2012-11-05 | ||
| US201361764466P | 2013-02-13 | 2013-02-13 | |
| US61/764,466 | 2013-02-13 | ||
| PCT/US2013/068237 WO2014071280A1 (en) | 2012-11-05 | 2013-11-04 | Treatment of cancer with pomalidomide in a renally impaired subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015535291A JP2015535291A (ja) | 2015-12-10 |
| JP2015535291A5 true JP2015535291A5 (ja) | 2016-12-28 |
Family
ID=50628132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540844A Pending JP2015535291A (ja) | 2012-11-05 | 2013-11-04 | 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150297579A1 (ja) |
| EP (1) | EP2914112A4 (ja) |
| JP (1) | JP2015535291A (ja) |
| CN (1) | CN104902754A (ja) |
| AU (1) | AU2013337352A1 (ja) |
| BR (1) | BR112015010039A2 (ja) |
| CA (1) | CA2889987A1 (ja) |
| EA (1) | EA201590883A1 (ja) |
| HK (1) | HK1214552A1 (ja) |
| IL (1) | IL238563A0 (ja) |
| MX (1) | MX2015005548A (ja) |
| NI (1) | NI201500063A (ja) |
| PH (1) | PH12015501002A1 (ja) |
| SG (1) | SG11201503456TA (ja) |
| WO (1) | WO2014071280A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2907908A1 (en) | 2013-04-02 | 2014-10-09 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| CN114907271B (zh) * | 2015-05-22 | 2024-05-07 | 转化药物开发有限责任公司 | 苯甲酰胺和活性化合物的组合物及其使用方法 |
| CN105456232A (zh) * | 2015-09-08 | 2016-04-06 | 刘剑 | 一种泊马度胺速溶膜剂及其制备方法 |
| CN109071460B (zh) * | 2016-03-02 | 2022-08-09 | 转化药物开发有限责任公司 | 氨基苯并咪唑衍生物 |
| WO2018013689A1 (en) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof |
| CN108721304B (zh) * | 2017-04-17 | 2020-10-16 | 北京大学 | 用于治疗肿瘤的药物组合物及其用途 |
| AU2018328308A1 (en) * | 2017-09-06 | 2020-04-16 | Translational Drug Development, Llc | Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase |
| GB202012160D0 (en) * | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
| WO2023158486A2 (en) * | 2022-02-15 | 2023-08-24 | The Broad Institute, Inc. | Cell-type specific targeting contractile injection system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JP5339588B2 (ja) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬 |
| WO2011125911A1 (ja) * | 2010-03-31 | 2011-10-13 | 国立大学法人金沢大学 | 金属錯体およびこれを有効成分として含有する抗がん剤 |
| EP2699909A1 (en) * | 2011-04-18 | 2014-02-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| KR20140024914A (ko) * | 2011-04-29 | 2014-03-03 | 셀진 코포레이션 | 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법 |
-
2013
- 2013-11-04 WO PCT/US2013/068237 patent/WO2014071280A1/en active Application Filing
- 2013-11-04 SG SG11201503456TA patent/SG11201503456TA/en unknown
- 2013-11-04 US US14/440,333 patent/US20150297579A1/en not_active Abandoned
- 2013-11-04 CA CA2889987A patent/CA2889987A1/en not_active Abandoned
- 2013-11-04 AU AU2013337352A patent/AU2013337352A1/en not_active Abandoned
- 2013-11-04 CN CN201380069405.4A patent/CN104902754A/zh active Pending
- 2013-11-04 EP EP13850977.3A patent/EP2914112A4/en not_active Withdrawn
- 2013-11-04 MX MX2015005548A patent/MX2015005548A/es unknown
- 2013-11-04 BR BR112015010039A patent/BR112015010039A2/pt not_active IP Right Cessation
- 2013-11-04 EA EA201590883A patent/EA201590883A1/ru unknown
- 2013-11-04 JP JP2015540844A patent/JP2015535291A/ja active Pending
-
2015
- 2015-04-30 IL IL238563A patent/IL238563A0/en unknown
- 2015-05-04 NI NI201500063A patent/NI201500063A/es unknown
- 2015-05-05 PH PH12015501002A patent/PH12015501002A1/en unknown
-
2016
- 2016-03-07 HK HK16102558.2A patent/HK1214552A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535291A5 (ja) | ||
| HK1214503A1 (zh) | 檸檬酸鐵在治療慢性腎臟疾病患者中的應用 | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| JP2015503422A5 (ja) | ||
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| JP2012143233A5 (ja) | ||
| JP2014530840A5 (ja) | ||
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| PH12015501002A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
| JP2015522522A5 (ja) | ||
| JP2014507659A5 (ja) | ||
| HK1223031A1 (zh) | 用於降低慢性腎病患者的心力衰竭的枸櫞酸鐵 | |
| JP2015502958A5 (ja) | ||
| CR20160037A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán | |
| EA201591450A1 (ru) | Фармацевтический состав, содержащий гликозаминогликан | |
| EP2959905A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959908A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| BRPI1009322A2 (pt) | dose de ave5026 para o tratamento de tromboembolia venosa em pacientes com deficiência renal grave | |
| JP2014526564A5 (ja) | ||
| EP2959907A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE | |
| JP2019528267A5 (ja) | ||
| JP2017516883A5 (ja) | ||
| HK1198128A1 (en) | Use of arctigenin in the preparation of medicament for the treatment of gastrointestinal ulcer diseases |